I-Mab
IMAB4.630USD
0.000
Close 12/26, 16:00（ET）Quotes delayed by 15 min
378.67MMarket Cap
LossP/E TTM
More Details of I-Mab Company
Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.
I-Mab Info
Ticker SymbolIMAB
Company nameNovaBridge Biosciences
IPO dateJan 17, 2020
CEOFu (Xi-Yong)
Number of employees32
Security typeDepository Receipt
Fiscal year-endJan 17
AddressSuite 400, 2440 Research Blvd
CityROCKVILLE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code20850
Phone13016702800
Websitehttp://www.novabridge.com/#/
Ticker SymbolIMAB
IPO dateJan 17, 2020
CEOFu (Xi-Yong)
Company Executives of I-Mab
Name
Name/Position
Position
Shareholding
Change
Dr. Robert Lenz, M.D., Ph.D.
Dr. Robert Lenz, M.D., Ph.D.
Independent Director
Independent Director
--
--
,
,
Independent Director
Independent Director
--
--
Mr. Wei Fu
Mr. Wei Fu
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Xi-Yong (Sean) Fu, Ph.D.
Dr. Xi-Yong (Sean) Fu, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Phillip Dennis, M.D., Ph.D.
Dr. Phillip Dennis, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Chun Kwok (Alan) Au
Mr. Chun Kwok (Alan) Au
Independent Director
Independent Director
--
--
Mr. Chia-Hung (Conor) Yang
Mr. Chia-Hung (Conor) Yang
Independent Director
Independent Director
--
--
Mr. Claire Xu
Mr. Claire Xu
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Mr. Kyler Lei
Mr. Kyler Lei
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Robert Lenz, M.D., Ph.D.
Dr. Robert Lenz, M.D., Ph.D.
Independent Director
Independent Director
--
--
,
,
Independent Director
Independent Director
--
--
Mr. Wei Fu
Mr. Wei Fu
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Xi-Yong (Sean) Fu, Ph.D.
Dr. Xi-Yong (Sean) Fu, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Phillip Dennis, M.D., Ph.D.
Dr. Phillip Dennis, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Chun Kwok (Alan) Au
Mr. Chun Kwok (Alan) Au
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
China (Mainland)
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Everest Medicines Ltd
13.74%
CBC Group
10.37%
T Investment Ltd
7.09%
Janus Henderson Investors
6.93%
HHLR Advisors, Ltd.
5.19%
Other
56.68%
Shareholders
Shareholders
Proportion
Everest Medicines Ltd
13.74%
CBC Group
10.37%
T Investment Ltd
7.09%
Janus Henderson Investors
6.93%
HHLR Advisors, Ltd.
5.19%
Other
56.68%
Shareholder Types
Shareholders
Proportion
Corporation
20.83%
Investment Advisor/Hedge Fund
14.71%
Private Equity
10.37%
Hedge Fund
7.26%
Investment Advisor
3.55%
Research Firm
2.06%
Individual Investor
0.56%
Venture Capital
0.26%
Sovereign Wealth Fund
0.06%
Other
40.34%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
108
25.11M
21.79%
-19.02M
2025Q2
118
35.60M
36.28%
-16.36M
2025Q1
125
33.28M
40.75%
-18.83M
2024Q4
137
31.58M
39.04%
-19.85M
2024Q3
150
39.14M
48.39%
-19.95M
2024Q2
195
40.08M
49.56%
-22.86M
2024Q1
267
37.63M
46.01%
-10.84M
2023Q4
298
37.94M
46.39%
-12.75M
2023Q3
330
40.42M
49.01%
-6.90M
2023Q2
347
43.88M
53.19%
-8.64M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Everest Medicines Ltd
15.85M
13.75%
+15.85M
--
Aug 05, 2025
CBC Group
11.95M
10.37%
-2.64M
-18.11%
Aug 05, 2025
T Investment Ltd
8.17M
7.09%
--
--
Mar 19, 2025
HHLR Advisors, Ltd.
5.98M
5.19%
--
--
Jun 30, 2025
Ariose Capital Management Limited
96.45K
0.08%
+96.45K
--
Jun 30, 2025
Candriam Luxembourg S.A.
1.13M
0.98%
--
--
Aug 31, 2025
Morgan Stanley & Co. LLC
58.30K
0.05%
+23.48K
+67.43%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ALPS Barron's 400 ETF
0.3%
SPDR S&P Emerging Markets Small Cap ETF
0.04%
SPDR S&P China ETF
0.01%
SPDR Portfolio Emerging Markets ETF
0.01%
ActivePassive International Equity ETF
0%
Invesco Golden Dragon China ETF
0%
SPDR S&P Emerging Asia Pacific ETF
0%
Avantis Emerging Markets Small Cap Equity ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
ALPS Barron's 400 ETF
Proportion0.3%
SPDR S&P Emerging Markets Small Cap ETF
Proportion0.04%
SPDR S&P China ETF
Proportion0.01%
SPDR Portfolio Emerging Markets ETF
Proportion0.01%
ActivePassive International Equity ETF
Proportion0%
Invesco Golden Dragon China ETF
Proportion0%
SPDR S&P Emerging Asia Pacific ETF
Proportion0%
Avantis Emerging Markets Small Cap Equity ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of I-Mab?
The top five shareholders of I-Mab are:
Everest Medicines Ltd holds 15.85M shares, accounting for 13.75% of the total shares.
CBC Group holds 11.95M shares, accounting for 10.37% of the total shares.
T Investment Ltd holds 8.17M shares, accounting for 7.09% of the total shares.
HHLR Advisors, Ltd. holds 5.98M shares, accounting for 5.19% of the total shares.
Ariose Capital Management Limited holds 96.45K shares, accounting for 0.08% of the total shares.
Everest Medicines Ltd holds 15.85M shares, accounting for 13.75% of the total shares.
CBC Group holds 11.95M shares, accounting for 10.37% of the total shares.
T Investment Ltd holds 8.17M shares, accounting for 7.09% of the total shares.
HHLR Advisors, Ltd. holds 5.98M shares, accounting for 5.19% of the total shares.
Ariose Capital Management Limited holds 96.45K shares, accounting for 0.08% of the total shares.
What are the top three shareholder types of I-Mab?
The top three shareholder types of I-Mab are:
Everest Medicines Ltd
CBC Group
T Investment Ltd
Everest Medicines Ltd
CBC Group
T Investment Ltd
How many institutions hold shares of I-Mab (IMAB)?
As of 2025Q3, 108 institutions hold shares of I-Mab, with a combined market value of approximately 25.11M, accounting for 21.79% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -14.49%.
What is the biggest source of revenue for I-Mab?
In FY2024, the -- business generated the highest revenue for I-Mab, amounting to -- and accounting for --% of total revenue.
